The Patent Finder
US

Topical Pharmaceutical Compositions

US 11,617,724 In force
OverviewFamilyAssignmentsSources & methods

Also listed on GlaxoSmithKline Intellectual Property Development Limited, an earlier holder on the record. The recorded assignments below show how it moved.

Collateral for a security interest recorded May 17, 2021 (U.S. Bank National Association).

Term ends May 19, 2036 · High confidence

Filed Nov 9, 2017 as application 15/807,682 · Granted Apr 4, 2023
Base term plus 206 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
20 years from filing
2016 2036
Clock starts
May 19, 2016
Term ends
May 19, 2036
Granted
Apr 4, 2023
base term fee events Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
206
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 10,195,160, US 11,458,108, US 11,622,945.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
8
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term runs 206 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 1 of 3 maintenance fees is paid so far. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts May 19, 2016, when application 15/158,858, the earliest non-provisional in its chain, was filed (this one was filed Nov 9, 2017)May 19, 2036High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustment+206 days, USPTO patent term adjustment recordDec 11, 2036High confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 10,195,160, US 11,458,108, US 11,622,945)capped to May 19, 2036High confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events1 of 3 maintenance fees paidIn forceHigh confidence
Computed term endThe steps above, in orderMay 19, 2036High confidence

This family

US 10,195,160In force
May 2036
May 2036
US 11,617,724this patent
May 2036
May 2036
US 11,458,108In force
May 2036
May 2036
US 11,622,945In force
May 2036
May 2036
US 10,426,743In force
May 2036
May 2036
US 11,612,573In force
May 2036
May 2036
Application 18/066,945Pending
not computed
not computed
Application 18/643,595Abandoned
not computed
not computed
The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Aug 24, 2018
Reel 46697, frame 848
Dermavant Sciences GmbHNovaquest Co.-Investment Fund VIII, L.P.Security Interest
Mar 12, 2019
Reel 48574, frame 173
Sonti, Sujatha D.; Lenn, Jon D.; Santos, Leandro L.; Whiteman, Justin E.; Doherty, Michael Quinn; Bedard, Mary; GlaxoSmithKline LLC; GlaxoSmithKline Research and Development LimitedGlaxoSmithKline Intellectual Property Development LimitedAssignment of Assignor's Interest
Mar 12, 2019
Reel 48574, frame 500
Jain, Piyush; GlaxoSmithKline LLC; GlaxoSmithKline Research and Development LimitedGlaxoSmithKline Intellectual Property Development LimitedAssignment of Assignor's Interest
Mar 12, 2019
Reel 48577, frame 304
Glaxo Group Limited; GlaxoSmithKline Intellectual Property Development LimitedDermavant Sciences GmbHAssignment of Assignor's Interest
May 24, 2019
Reel 49285, frame 377
Dermavant Sciences GmbHHercules Capital, Inc., as AgentIntellectual Property Security Agreement
Dec 18, 2019
Reel 51320, frame 993
Thomas, Joey Roger; GlaxoSmithKline LLC; GlaxoSmithKline Research and Development LimitedGlaxoSmithKline Intellectual Property Development LimitedAssignment of Assignor's Interest
Oct 15, 2020
Reel 54070, frame 515
Thomas, Joey Roger; GlaxoSmithKline LLC; GlaxoSmithKline Research and Development LimitedGlaxoSmithKline Intellectual Property Development LimitedAssignment of Assignor's Interest
May 17, 2021
Reel 56261, frame 437
Dermavant Sciences GmbHU.S. Bank National AssociationSecurity Interest
May 19, 2021
Reel 56399, frame 778
Dermavant Sciences GmbHU.S. Bank National AssociationSecurity Interest
Sep 3, 2024
Reel 68471, frame 692
Hercules Capital, Inc., as AgentDermavant Sciences GmbHRelease of Security Interest
Oct 29, 2024
Reel 69274, frame 101
US Bank Trust Company, National AssociationDermavent Sciences GmbHRelease of Security Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited